MA29629B1 - Inhibiteurs de l'histone deacetylase - Google Patents

Inhibiteurs de l'histone deacetylase

Info

Publication number
MA29629B1
MA29629B1 MA30571A MA30571A MA29629B1 MA 29629 B1 MA29629 B1 MA 29629B1 MA 30571 A MA30571 A MA 30571A MA 30571 A MA30571 A MA 30571A MA 29629 B1 MA29629 B1 MA 29629B1
Authority
MA
Morocco
Prior art keywords
inhibitors
histone deacetylase
methods
kits
compounds
Prior art date
Application number
MA30571A
Other languages
English (en)
Inventor
Jerome C Bressi
Anthony R Gangloff
Lily Kwok
Original Assignee
Takeda San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda San Diego Inc filed Critical Takeda San Diego Inc
Publication of MA29629B1 publication Critical patent/MA29629B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

[0495] L'invention fournit des composés, compositions pharmaceutiques, trousses, méthodes et procédés destinés à être utilisés avec des HDAC, lesquels composés, compositions, trousses et méthodes comprennent un composé choisi dans le groupe consistant en : dans laquelle les substituants sont tels que définis ici.
MA30571A 2005-07-14 2008-01-14 Inhibiteurs de l'histone deacetylase MA29629B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69913905P 2005-07-14 2005-07-14

Publications (1)

Publication Number Publication Date
MA29629B1 true MA29629B1 (fr) 2008-07-01

Family

ID=37075806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30571A MA29629B1 (fr) 2005-07-14 2008-01-14 Inhibiteurs de l'histone deacetylase

Country Status (18)

Country Link
US (7) US7732475B2 (fr)
EP (1) EP1904452A2 (fr)
JP (1) JP2009501236A (fr)
KR (1) KR20080032188A (fr)
CN (1) CN101263121A (fr)
AR (1) AR054866A1 (fr)
AU (1) AU2006270322A1 (fr)
BR (1) BRPI0613429A2 (fr)
CA (1) CA2615105A1 (fr)
CR (1) CR9664A (fr)
EA (1) EA200800321A1 (fr)
IL (1) IL188692A0 (fr)
MA (1) MA29629B1 (fr)
NO (1) NO20080784L (fr)
PE (1) PE20070195A1 (fr)
TW (1) TW200740761A (fr)
WO (1) WO2007011626A2 (fr)
ZA (1) ZA200800901B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006122319A2 (fr) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
US8088951B2 (en) * 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
CL2008000150A1 (es) * 2007-01-18 2008-03-14 Takeda San Diego Inc Formas cristalinas de compuestos derivados de n-(2-amino fenil)-4-pirazol-1-il metil benzamida; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico que comprende a dichos compuestos; y su uso para tratar cancer, psoriasis, ar
EP2134683A2 (fr) * 2007-02-12 2009-12-23 Intermune, Inc. Nouveaux inhibiteurs de réplication du virus de l'hépatite c
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
CN103087043A (zh) * 2007-03-16 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
AU2008269154B2 (en) * 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP5469604B2 (ja) * 2007-09-19 2014-04-16 ４エスツェー アクチェンゲゼルシャフト 新規テトラヒドロ融合ピリジン
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
EP2242367A4 (fr) * 2008-01-08 2012-07-04 Univ Pennsylvania Inhibiteurs de rel et leurs procédés d'utilisation
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
IN2012DN03807A (fr) 2009-10-30 2015-08-28 Massachusetts Inst Technology
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
CA2862289C (fr) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations
JP5881460B2 (ja) * 2012-02-23 2016-03-09 公立大学法人名古屋市立大学 新規アミド化合物及びその用途
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
PT2970139T (pt) 2013-03-15 2018-08-01 Biomarin Pharm Inc Inibidores de hdac
WO2014151142A1 (fr) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
WO2015023915A1 (fr) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
WO2015143652A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015157504A1 (fr) 2014-04-11 2015-10-15 Taipei Medical University Inhibiteurs de l'histone désacétylase
WO2015190700A1 (fr) * 2014-06-11 2015-12-17 성균관대학교산학협력단 Composition pour la prévention ou le traitement de la sepsie
US10478431B2 (en) 2014-11-26 2019-11-19 The J. David Gladstone Institutes Methods for treating a cytomegalovirus infection
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016183266A1 (fr) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017015451A1 (fr) * 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
US10301255B2 (en) * 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PL3328843T3 (pl) * 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CA3001666C (fr) 2015-10-12 2021-03-30 Chong Kun Dang Pharmaceutical Corp. Composes derives d'oxadiazole amine utilises en tant qu'inhibiteur de l'histone desacetylase 6, et composition pharmaceutique les comprenant
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
US9728231B1 (en) * 2016-05-03 2017-08-08 Taiwan Semiconductor Manufacturing Co., Ltd. Device and method for data-writing
WO2017207983A1 (fr) 2016-05-31 2017-12-07 Kalvista Pharmaceuticals Limited Dérivés de pyrazole en tant qu'inhibiteurs de la kallicréine plasmatique
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
SG11201810834WA (en) 2016-06-10 2018-12-28 Enanta Pharm Inc Hepatitis b antiviral agents
EP3529242A1 (fr) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthèse d'inhibiteurs d'ezh2
TW201829381A (zh) * 2016-12-22 2018-08-16 美商拜奧馬林製藥公司 組蛋白脫乙醯基酶抑制劑
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
CN109232358A (zh) * 2017-07-10 2019-01-18 复旦大学 吲哚类衍生物或其盐及其制备方法和用途
EA202090514A1 (ru) 2017-08-28 2020-06-24 Энанта Фармасьютикалс, Инк. Противовирусное средство против гепатита в
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
JP7078722B2 (ja) 2017-11-29 2022-05-31 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレイン阻害剤を含む剤形
TW201927789A (zh) 2017-12-06 2019-07-16 美商因那塔製藥公司 B型肝炎抗病毒試劑
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019143902A2 (fr) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Hétérocycles substitués utiles en tant qu'agents antiviraux
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019241435A1 (fr) 2018-06-12 2019-12-19 The J. David Gladstone Institutes Compositions pour interruption de circuit de rétroaction transcriptionnelle de virus de l'herpès et utilisations correspondantes
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CA3113235A1 (fr) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Heterocycles fonctionnalises utiles en tant qu'agents antiviraux
JP2022504703A (ja) * 2018-10-10 2022-01-13 リージェナシー・ファーマシューティカルズ・エルエルシー ピリミジン及びピラジンｈｄａｃ１、２阻害剤
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
JP7489689B2 (ja) * 2018-11-28 2024-05-24 株式会社日本フォトサイエンス 紫外線処理方法及びシステム
WO2020186101A1 (fr) 2019-03-12 2020-09-17 The Broad Institute, Inc. Procédés de détection, compositions et méthodes de modulation des cellules de sarcome synovial
MY207444A (en) 2019-05-31 2025-02-27 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247561A1 (fr) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Agents antiviraux de l'hépatite b
WO2020247575A1 (fr) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
WO2021007488A1 (fr) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Hétérocycles substitués utilisés en tant qu'agents antiviraux
WO2021021979A2 (fr) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Inhibiteurs de hdac6 et leurs utilisations
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
JP7823945B2 (ja) * 2022-03-17 2026-03-04 スンミョン ウィメンズ ユニヴァーシティ インダストリー アカデミック コーポレーション ファウンデーション 新規なヘテロ環ヒストン脱アセチル化酵素阻害剤及びそれを含む薬学組成物
EP4504190A4 (fr) 2022-04-08 2026-03-25 Eikonizo Therapeutics Inc Inhibiteurs d'oxadiazole hdac6 et leurs utilisations

Family Cites Families (322)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US794392A (en) * 1904-01-29 1905-07-11 Nat Tube Co Bending-roll.
US4482571A (en) 1982-06-21 1984-11-13 University Of Pittsburgh Sickle cell anemia treatment and compound
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IE862737L (en) 1985-10-17 1987-04-17 Staehler Theo Heterocyclic compounds
US4964895A (en) 1987-06-08 1990-10-23 Monsanto Company Substituted 4-(4-nitrophenoxy) pyrazoles and their use as herbicides
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
IE900394L (en) * 1989-02-08 1990-08-08 Abbott Lab Thiazole derivatives
US5216004A (en) * 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5439939A (en) 1992-03-17 1995-08-08 Children's Hospital Medical Center Of Northern California Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
RO115498B1 (ro) * 1993-10-29 2000-03-30 Univ Boston Metoda de tratament a neoplasmului
WO1995013062A1 (fr) 1993-11-10 1995-05-18 Sloan-Kettering Institute For Cancer Research Esters butyriques utilises comme agents pour induire une differentiation cellulaire
US5569675A (en) 1994-03-07 1996-10-29 Bar Ilan University Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US6040342A (en) * 1994-09-16 2000-03-21 Bar-Ilan University Retinoyloxy (alkyl-substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US5922837A (en) 1995-09-20 1999-07-13 Merck & Co., Inc. Antiprotozoal cyclic tetrapeptides
JPH11514857A (ja) 1995-09-20 1999-12-21 メルク エンド カンパニー インコーポレーテッド 抗原虫剤の標的としてのヒストンデアセチラーゼ
US20030219832A1 (en) 1996-03-11 2003-11-27 Klein Elliott S. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1997047307A1 (fr) 1996-06-14 1997-12-18 The Uab Research Foundation Utilisation d'inhibiteurs d'histone-deacetylase destines a activer l'expression transgenique
CA2258593A1 (fr) 1996-07-02 1998-01-08 Abraham Nudelman Retinoyloxy-alkylene butyrates (substitues) utiles pour le traitement du cancer et autres maladies proliferatives
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5939456A (en) 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
EP0827742A1 (fr) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Utilisation des inhibiteurs de l'histone déacétylase pour le traitement de la fibrose ou de la cirrhose
US6068987A (en) * 1996-09-20 2000-05-30 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
US6235474B1 (en) * 1996-12-30 2001-05-22 The Johns Hopkins University Methods and kits for diagnosing and determination of the predisposition for diseases
US6130248A (en) 1996-12-30 2000-10-10 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
AU5617398A (en) 1996-12-30 1998-07-31 Beacon Laboratories L.L.C. Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US7062219B2 (en) 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6110970A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6110955A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
KR20010023449A (ko) 1997-09-02 2001-03-26 나가시마 카쭈시게, 노미야마 아키히코 신규한 환상 테트라펩티드 유도체 및 그 의약 용도
EP1037533A1 (fr) 1997-11-10 2000-09-27 The Salk Institute for Biological Studies Methodes d'utilisation d'inhibiteurs de co-represseurs dans le cadre du traitement de maladies neoplasiques
US6884597B1 (en) * 1998-01-20 2005-04-26 Medical & Biological Laboratories, Co., Ltd. Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
CA2324426A1 (fr) 1998-02-11 1999-08-19 Douglas V. Faller Compositions et techniques de traitement de la mucoviscidose
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US20030236204A1 (en) * 2002-06-14 2003-12-25 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 2 expression
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
WO2000010583A1 (fr) 1998-08-21 2000-03-02 Smithkline Beecham Corporation Gene humain de l'histone deacetylase hd4
DE19842506A1 (de) 1998-09-17 2000-03-23 Volkswagen Ag Verfahren und Vorrichtung zur Überwachung von Signalen bei vernetzten Systemen
TR200101049T2 (tr) 1998-10-13 2002-01-21 Fujisawa Pharmaceutical Co. Ltd. Siklik tetrapeptid bileşiği ve kullanımı
EP1129175A2 (fr) 1998-10-16 2001-09-05 Novartis AG Procede pour favoriser l'autorenouvellement et transduction genique amelioree des cellules souches hematopoietiques par des inhibiteurs de desacetylase de l'histone
JP2002541762A (ja) * 1998-11-10 2002-12-10 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｍｅｆ２転写因子の阻害による心肥大および心不全の予防方法
US6287790B1 (en) 1998-11-30 2001-09-11 The Regents Of The University Of California Utilization of nuclear structural proteins for targeted therapy and detection of proliferative and differentiation disorders
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
EP1164198B1 (fr) 1999-03-23 2006-06-07 Chugai Seiyaku Kabushiki Kaisha Methode de criblage d'agents anticancereux
US6518012B1 (en) * 1999-04-02 2003-02-11 Health Research, Inc. Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
US20030078216A1 (en) 1999-05-03 2003-04-24 Macleod A. Robert Inhibition of histone deactylase
WO2000071703A2 (fr) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition d'histone deacetylase
AU6109600A (en) 1999-07-23 2001-02-13 Merck & Co., Inc. Apicidin-derived cyclic tetrapeptides
US20030078369A1 (en) 1999-07-23 2003-04-24 Meinke Peter T. Apicidin-derived cyclic tetrapeptides
CA2382045A1 (fr) 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Methodes et compositions relatives a la regulation par hdac 4 ou 5 de l'expression genique au niveau cardiaque
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
AU7108400A (en) 1999-09-03 2001-04-10 Salk Institute For Biological Studies, The Modulation of gene expression by modulating histone acetylation
MXPA02002505A (es) * 1999-09-08 2004-09-10 Sloan Kettering Inst Cancer Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos.
WO2001018045A1 (fr) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Structure cristalline d'une deacetylase et ses inhibiteurs
CA2386299A1 (fr) 1999-10-08 2001-04-19 Merck & Co., Inc. Inhibiteurs d'histone acetyle transferase antiprotozoaire
CA2391952C (fr) 1999-11-23 2012-01-31 Methylgene Inc. Inhibiteurs de l'histone deacetylase
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
CA2291367A1 (fr) * 1999-12-06 2001-06-06 Isabelle Henry Assemblages genetiques possedant un nombre reduit ou accru de zones de controle epigenetiques et methodes pour leur utilisation
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
CA2393682C (fr) 1999-12-08 2012-01-31 Xcyte Therapies, Inc. Depsipeptide et ses congeneres destines a etre utilises en tant qu'immunodepresseurs
WO2001042437A2 (fr) 1999-12-08 2001-06-14 Axys Pharmaceuticals, Inc. Proteines histone deacetylase-8, acides nucleiques et technique d'utilisation
US6875598B1 (en) * 1999-12-08 2005-04-05 Applera Corporation Histone deacetylase-8 proteins, nuclei acids, and methods for use
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6544957B2 (en) 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
DE60143192D1 (de) * 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
ES2254385T3 (es) * 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
GB0005199D0 (en) 2000-03-04 2000-04-26 Imp College Innovations Ltd Modulation of histone deacetylase
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002008273A2 (fr) 2000-07-21 2002-01-31 Millennium Pharmaceuticals, Inc. 47508, un nouveau membre de la famille de l'histone deacetylase humaine et utilisations associees
US20020137162A1 (en) 2000-03-24 2002-09-26 Zuomei Li Antisense oligonucleotide inhibition of specific histone deacetylase isoforms
AU2001250963A1 (en) 2000-03-24 2001-10-08 Filgen Biosciences, Inc. Peptides binding to non-acetylated H3 and H4 histones for cancer therapy
GB0007217D0 (en) 2000-03-24 2000-05-17 Europ I Of Oncology Materials and methods relating to the treatment of leukaemias
EP1438404A2 (fr) * 2000-03-24 2004-07-21 Methylgene, Inc. Inhibition d'isoformes specifiques d'histone deacetylase
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
EP1170008A1 (fr) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Acide valproique et ses dérivés en tant qu' inhibiteurs de la déacétylase de l' histone
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
EP1310485A4 (fr) 2000-07-28 2005-07-20 Sumitomo Pharma Derives du pyrrole
US6673587B1 (en) * 2000-08-11 2004-01-06 The Salk Institute For Biological Studies Histone deacetylase, and uses therefor
EP1182263A1 (fr) 2000-08-11 2002-02-27 Evotec OAI AG Procédé de détection d'une activité thréonine- ou sérine kinase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002022133A1 (fr) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion de l'apoptose dans des cellules cancereuses par co-administration d'inhibiteurs de la kinase dependante de la cycline, et d'agents de differentiation cellulaire
US6538030B2 (en) 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
JP4975941B2 (ja) * 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
WO2002026696A1 (fr) 2000-09-29 2002-04-04 Prolifix Limited Composes d'acide carbamique comprenant un enchainement amide comme inhibiteurs hdac
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
WO2002030970A2 (fr) 2000-10-13 2002-04-18 Bayer Aktiengesellschaft Regulation de l'histone deacetylase humaine
DE10053474A1 (de) 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
US20040043470A1 (en) * 2000-10-31 2004-03-04 Yonghong Xiao Regulation of human histone deacetylase
AU2002228771B2 (en) 2000-11-02 2007-10-25 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to HSP90
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
DE10061162A1 (de) 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
AR035659A1 (es) * 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US20040005574A1 (en) * 2002-07-08 2004-01-08 Leonard Guarente SIR2 activity
US6376508B1 (en) * 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
AU2002230997A1 (en) 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20050171042A1 (en) 2000-12-19 2005-08-04 Monia Brett P. Compositions and their uses directed to binding proteins
US20040204373A1 (en) 2000-12-19 2004-10-14 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase I expression
US6693132B2 (en) 2000-12-21 2004-02-17 Beacon Laboratories, Inc. Methods for using alkanoyloxymethyl esters
AU2002237240A1 (en) * 2000-12-20 2002-07-01 Novartis Ag Histone deacetylase-related gene and protein
US6562995B1 (en) 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
US6720445B2 (en) * 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
WO2002051846A1 (fr) * 2000-12-22 2002-07-04 Zee, Ok Pyo Derives d'apicidine, procedes de synthese de ceux-ci, et compositions antitumorales contenant ces derives
AR035513A1 (es) * 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
JP2005507231A (ja) 2001-01-10 2005-03-17 アメリカ合衆国 甲状腺新生物の診断および治療におけるヒストン脱アセチル酵素阻害剤
US20030148970A1 (en) 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
WO2002069947A2 (fr) 2001-01-12 2002-09-12 Methylgene, Inc. Procede permettant d'inhiber specifiquement l'histone deacetylase-4
US20030152557A1 (en) 2001-01-12 2003-08-14 Besterman Jeffrey M. Methods for inhibiting histone deacetylase-4
US6756200B2 (en) * 2001-01-26 2004-06-29 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
AR035417A1 (es) 2001-01-27 2004-05-26 Hoffmann La Roche Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
WO2002060430A1 (fr) 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Utilisation de retinoides et d'inhibiteurs de l'histone deacetylase pour inhiber la croissance des tumeurs solides
AU2002233314A1 (en) * 2001-02-05 2002-09-19 Bayer Aktiengesellschaft Regulation of human histone acetyltransferase
US20020177594A1 (en) 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
CA2442366C (fr) 2001-03-27 2012-09-25 Circagen Pharmaceutical, Llc Inhibiteurs de l'histone deacetylase
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
DE60113645T2 (de) 2001-04-10 2006-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
AU2002305523A1 (en) 2001-05-09 2002-11-18 President And Fellows Of Harvard College Dioxanes and uses thereof
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
CA2450129A1 (fr) 2001-06-14 2002-12-27 Donald G. Jackson Nouvelles histones deacetylases humaines
EP1409661A4 (fr) 2001-06-14 2006-02-01 Sloan Kettering Inst Cancer Polypeptides d'hdac9, polynucleotides et leurs utilisations
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
WO2002102981A2 (fr) 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York Procedes therapeutiques et prophylactiques a base de sir2$g(a)
WO2002102316A2 (fr) 2001-06-19 2002-12-27 The Regents Of The University Of California Histone-deacetylase et procedes d'utilisation correspondants
WO2003000715A1 (fr) 2001-06-22 2003-01-03 Ceres, Inc. Polypeptides d'histone acetyltransferase chimeriques
WO2003004050A1 (fr) 2001-07-03 2003-01-16 University Of Virginia Patent Foundation Methylation de l'histone h4 au niveau de l'arginine 3
WO2003014340A2 (fr) 2001-08-03 2003-02-20 Novartis Ag Gene et proteine associes aux histones desacetylases
US20040266718A1 (en) 2001-08-06 2004-12-30 Zuomei Li Inhibition of specific histone deacetylase isoforms
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
DK1426054T3 (da) 2001-08-21 2011-12-12 Astellas Pharma Inc Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
US20040259772A1 (en) 2001-08-24 2004-12-23 Antonio Fojo Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1291015A1 (fr) 2001-09-10 2003-03-12 Lunamed AG Compositions à libération prolongée d'un agent actif
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003024448A2 (fr) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibiteurs de l'histone-deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1293205A1 (fr) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Acide valproique et ses dérivés pour la polythérapie du cancer humain et pour le traitement de la métastase de tumeurs et de la maladie residuelle imperceptible
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
GB0123664D0 (en) 2001-10-02 2001-11-21 Inst Of Cancer Res The Histone deacetylase 9
WO2003032921A2 (fr) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Traitement des maladies neurodegeneratives et du cancer du cerveau
WO2003033678A2 (fr) 2001-10-18 2003-04-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methodes d'utilisation d'inhibiteurs de la desacetylase afin de stimuler la differenciation et la regenerescence cellulaires
JP2003137866A (ja) 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体
NZ544689A (en) 2001-11-06 2007-08-31 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
AU2002356992A1 (en) 2001-11-21 2003-06-10 Albert Einstein College Of Medicine Of Yeshiva University Sir2 products and activities
US7514406B2 (en) * 2001-11-27 2009-04-07 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
JP2005511062A (ja) 2001-12-07 2005-04-28 ノバルティス アクチエンゲゼルシャフト タンパク質脱アセチル化酵素阻害剤についての生物マーカーとしてのアルファ−チューブリンアセチル化レベルの使用
AU2002351898A1 (en) 2001-12-21 2003-07-09 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
JP2005517683A (ja) 2001-12-28 2005-06-16 藤沢薬品工業株式会社 環状テトラペプチド化合物およびその用途
ITRM20020016A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US20030165956A1 (en) 2002-01-25 2003-09-04 Board Of Regents, The University Of Texas System Electrophoretic assay to predict risk of cancer and the efficacy and toxicity of cancer therapy
WO2003066889A2 (fr) 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Dosage permettant de mesurer l'activite d'acetylation ou de deacetylation d'une enzyme
JP2006505241A (ja) 2002-02-08 2006-02-16 ノバルティス アクチエンゲゼルシャフト Ｈｄａｃ阻害活性を有する化合物のスクリーニング法
EP1482962A4 (fr) 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer Methode de traitement des maladies mediees par la thioredoxine (trx)
WO2003070754A1 (fr) 2002-02-20 2003-08-28 Minoru Yoshida Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
JPWO2003070691A1 (ja) 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ550185A (en) * 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
CA2478592A1 (fr) 2002-03-07 2003-09-18 The Johns Hopkins University School Of Medicine Depistage genomique pour genes lies au cancer rendus epigenetiquement silencieux
CA2478510A1 (fr) * 2002-03-07 2003-09-18 The Johns Hopkins University Depistage genomique pour genes suppresseurs de tumeur rendus epigenetiquement silencieux
EA007270B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н.В. Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
ATE395343T1 (de) * 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
ES2306880T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inhibidores novedosos de la histona desacetilasa.
CA2476067C (fr) 2002-03-13 2011-09-20 Janssen Pharmaceutica N.V. Derives carbonylamino utilises en tant que nouveaux inhibiteurs d'histone deacetylase
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
WO2003080864A1 (fr) 2002-03-26 2003-10-02 Exhonit Therapeutics Sa Histone deacetylase: nouvelle cible moleculaire de la neurotoxicite
AU2003226014A1 (en) 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US6841565B1 (en) * 2002-03-29 2005-01-11 The Ohio State University Treatment of patients with chronic lymphocytic leukemia
BR0308908A (pt) 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
US8673888B2 (en) 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
AU2003219595A1 (en) 2002-04-11 2003-10-27 In2Gen Co., Ltd. Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
MY134200A (en) 2002-04-12 2007-11-30 Kowa Co Method for treating cancer
WO2003088954A1 (fr) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Polytherapie pour le traitement de cancer
US6620838B1 (en) * 2002-04-19 2003-09-16 Signal Pharmaceuticals, Inc. Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
US20030206946A1 (en) 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
NO20032183L (no) 2002-05-15 2003-11-17 Schering Ag Histon-deacetylase-inhibitor og anvendelse derav
US7351542B2 (en) * 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003243285A1 (en) 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
WO2003099272A1 (fr) 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Inhibiteurs d'histone desacetylase bases sur des composes alpha-ceto-epoxydes
AU2003247390A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc. Histone deacetylase inhibitors based on alphachalcogenmethylcarbonyl compounds
US20030224473A1 (en) 2002-05-23 2003-12-04 Mccafferty Dewey G. Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
AU2003237248A1 (en) * 2002-05-23 2003-12-12 The Regents Of The University Of California Methods of modulating mitochondrial nad-dependent deacetylase
US20040002447A1 (en) * 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
BR0311714A (pt) 2002-06-10 2005-03-01 Novartis Ag Combinações que compreendem epotilonas e seus usos farmacêuticos
JP2005529625A (ja) 2002-06-19 2005-10-06 オンコセラピー・サイエンス株式会社 結腸直腸腫瘍の診断のための方法
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
BR0305259A (pt) 2002-07-01 2004-10-05 Upjohn Co Inibidores de hcv ns5b polimerase
US20040072770A1 (en) 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
SE0202157D0 (sv) * 2002-07-09 2002-07-09 Biovitrum Ab Methods for identification of compounds modulating insulin resistance
US20060089410A1 (en) 2002-07-17 2006-04-27 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
US20040082565A1 (en) 2002-07-17 2004-04-29 Chemgenex Therapeutics, Inc. Formulations and methods of administration of cephalotaxines including homoharringtonine
DE10233412A1 (de) 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
US20050176686A1 (en) 2002-07-23 2005-08-11 4Sc Ag Novel compounds as histone deacetylase inhibitors
US20050065596A1 (en) * 2002-07-24 2005-03-24 Xufan Tseng Stents capable of controllably releasing histone deacetylase inhibitors
JP4508872B2 (ja) 2002-07-25 2010-07-21 ソニー株式会社 遺伝子転写調節剤
JP2005539001A (ja) 2002-08-02 2005-12-22 アージェンタ・ディスカバリー・リミテッド ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸
CA2495354A1 (fr) 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. Agent inhibant la degradation de la matrice extracellulaire du cartilage articulaire
WO2004020460A1 (fr) 2002-08-30 2004-03-11 Yamanouchi Pharmaceutical Co., Ltd. Nouveau compose depsipeptide
CA2498210C (fr) 2002-09-13 2011-10-18 Virginia Commonwealth University Combinaison de a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et b) d'un inhibiteur de l'histone deacetylase pour le traitement de la leucemie
EP1400806A1 (fr) 2002-09-18 2004-03-24 G2M Cancer Drugs AG Criblage pour inhibiteurs de l'histone déacétylase
CA2499189A1 (fr) 2002-09-19 2004-04-01 University Of South Florida Procede de traitement de la leucemie au moyen d'une combinaison d'acide hydromaxique suberoylanilide et d'imatinibe mesylate
EP1403639A1 (fr) 2002-09-30 2004-03-31 G2M Cancer Drugs AG Anticorps en tant que moyen de diagnostic lors d'un traitement par l'administration d'inhibiteurs de l'histone deacetylase
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US20040077084A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
EP1551795A1 (fr) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibiteurs de l'histone deacetylase
CA2504460A1 (fr) 2002-11-12 2004-05-27 Peter G. Klimko Inhibiteurs de l'histone desacetylase pour le traitement de maladies et de troubles oculaires, neovasculaires ou oedemateux
JP2006508120A (ja) 2002-11-12 2006-03-09 アルコン，インコーポレイテッド 眼の変性疾患を処置するためのヒストンデアセチラーゼインヒビター
AU2003295444A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP2006508986A (ja) 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
AU2003296310A1 (en) 2002-12-06 2004-06-30 University Of South Florida Histone deacetylase inhibitor enhancement of trail-induced apoptosis
TW200426138A (en) 2002-12-10 2004-12-01 Hoffmann La Roche Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
EP1590318A2 (fr) 2002-12-12 2005-11-02 Jawaharlal Nehru Centre For Advanced Scientific Research Modulateurs (inhibiteurs/activateurs) d'histone acetyltransferases
TW200418825A (en) 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
ITMI20022745A1 (it) 2002-12-23 2004-06-24 Coimex Scrl United Companies Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione.
EP1641458A2 (fr) 2002-12-27 2006-04-05 Schering Aktiengesellschaft Nouvelles associations pharmaceutiques de phthalazines (inhibiteurs vegf) et de benzamides (inhibiteurs hdfac)
US20040197888A1 (en) 2002-12-31 2004-10-07 Armour Christopher D. Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004064727A2 (fr) 2003-01-16 2004-08-05 Georgetown University Procedes pour utiliser des inhibiteurs de l'histone deacetylase en tant qu'agents synergiques dans la therapie du cancer
AU2004205372B2 (en) 2003-01-17 2011-02-24 Topotarget Uk Limited Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
WO2004067480A2 (fr) 2003-01-25 2004-08-12 Oxford Glycosciences (Uk) Ltd Derives de phenyluree substitues en tant qu'inhibiteurs d'hdac
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US7208491B2 (en) 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
WO2004072265A2 (fr) 2003-02-11 2004-08-26 Wyeth Procedes pour controler in vivo des activites de medicaments
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
AU2003900587A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US20040241856A1 (en) 2003-02-12 2004-12-02 Irm Llc, A Delaware Limited Liability Company Methods and compositions for modulating stem cells
WO2004071464A2 (fr) 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Applications therapeutiques et diagnostiques de genes s'exprimant de maniere differentielle dans des cellules souches lympho-hematopoietiques
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
EP1595952A4 (fr) 2003-02-19 2008-05-21 Astellas Pharma Inc Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase
WO2004076386A2 (fr) 2003-02-25 2004-09-10 Topotarget Uk Limited Composes d'acide carbamique comprenant un groupe heteroaryle bicyclique utilises en tant qu'inhibiteurs de hdac
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
JP2006523693A (ja) 2003-04-01 2006-10-19 メモリアル スローン−ケタリング キャンサー センター ヒドロキサム酸化合物およびその使用方法
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
PL1611088T3 (pl) 2003-04-07 2009-11-30 Pharmacyclics Inc Hydroksamiany jako środki terapeutyczne
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
MXPA05012464A (es) 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
MXPA05012619A (es) 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US7271195B2 (en) 2003-06-10 2007-09-18 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
EP1635800A2 (fr) 2003-06-10 2006-03-22 Kalypsys, Inc. Composes carbonyle utilises comme inhibiteurs de l'histone desacetylase a des fins therapeutiques
US20060235012A1 (en) 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
EP1491188A1 (fr) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Utilisation topique de l'acide valproique pour traiter des maladies de la peau
DK2238982T3 (da) 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
US20050096256A1 (en) 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
JP2007535475A (ja) 2003-07-02 2007-12-06 イェシバ・ユニバーシティ Ｓｉｒ２制御
US7842835B2 (en) * 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
EP1644323B1 (fr) 2003-07-07 2015-03-18 Georgetown University Inhibiteurs d'histone desacetylase et leurs procedes d'utilisation
EP1663201A4 (fr) 2003-07-15 2009-10-28 Korea Res Inst Of Bioscience Utilisation des nouveaux composes 2-oxo-heterocycliques et des compositions pharmaceutiques les contenant
GB0316889D0 (en) 2003-07-18 2003-08-20 Univ London Pharmaceutical agents
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
WO2005011598A2 (fr) 2003-07-31 2005-02-10 University Of South Florida Composition et methode de traitement de la leucemie
WO2005014588A1 (fr) 2003-08-01 2005-02-17 Argenta Discovery Limited Acides hydroxamiques de thienyle substitues presentant une activite de deacetylase
US20050032794A1 (en) * 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
JP2007501774A (ja) 2003-08-08 2007-02-01 ノバルティス アクチエンゲゼルシャフト スタウロスポリンを含む組み合わせ
WO2005019174A1 (fr) 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Derives d'acetylene en tant qu'inhibiteurs d'histone deacetylase
EP1663194B1 (fr) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Utilisation de SAHA pour traiter le mésotheliome
JP2007504131A (ja) 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US8404458B2 (en) 2003-09-16 2013-03-26 The Rockefeller University Histone modifications as binary switches controlling gene expression
AU2004271730A1 (en) 2003-09-18 2005-03-24 Novartis Ag Combination of a histone deacetylase inhibitor with a death receptor ligand
KR101127201B1 (ko) 2003-09-22 2012-04-12 에스*바이오 피티이 리미티드 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
CA2539117A1 (fr) 2003-09-24 2005-04-07 Methylgene Inc. Inhibiteurs d'histone deacetylase
CA2540108A1 (fr) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Agent antitumoral comprenant un inhibiteur de l'histone desacetylase et un inhibiteur de la topoisomerase ii
US7935724B2 (en) 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005040101A1 (fr) 2003-10-27 2005-05-06 S*Bio Pte Ltd Hydroxamates connectes a l'acyluree et a la sulfonyluree
US20070167499A1 (en) 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
IN2003CH00929A (fr) 2003-11-13 2008-10-06
WO2005053609A2 (fr) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante
CN1905881A (zh) 2003-11-26 2007-01-31 阿托恩药品公司 二胺和亚氨二醋酸异羟肟酸衍生物
EP1694640A4 (fr) 2003-11-28 2007-01-10 Univ Queensland Agents anticancereux
US9115090B2 (en) 2003-12-02 2015-08-25 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
WO2005058298A2 (fr) 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Analogues de fk228 et methodes de production et d'utilisation desdits analogues
EP1541549A1 (fr) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Dérivés tricycliques d'hydroxamate et de benzamide, compositions et methodes
WO2005066151A2 (fr) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
WO2005065681A1 (fr) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Derives de n-hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide et composes associes en tant qu'inhibiteurs d'histone deacetylase pour le traitement du cancer
US8652502B2 (en) 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
CN101247793B (zh) 2003-12-29 2013-04-10 哈佛大学校长及研究员协会 治疗或预防肥胖和胰岛素抗性病症的组合物
US20090253769A1 (en) 2004-01-21 2009-10-08 Gessica Filocamo Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1735319B1 (fr) 2004-03-26 2017-05-03 MethylGene Inc. Inhibiteurs d'histone desacetylase

Also Published As

Publication number Publication date
JP2009501236A (ja) 2009-01-15
US20080114037A1 (en) 2008-05-15
WO2007011626A3 (fr) 2007-05-03
TW200740761A (en) 2007-11-01
US7741494B2 (en) 2010-06-22
NO20080784L (no) 2008-03-31
ZA200800901B (en) 2010-05-26
US20080119648A1 (en) 2008-05-22
CA2615105A1 (fr) 2007-01-25
US20080119658A1 (en) 2008-05-22
US20090111996A1 (en) 2009-04-30
EP1904452A2 (fr) 2008-04-02
CN101263121A (zh) 2008-09-10
BRPI0613429A2 (pt) 2009-02-10
US20070015809A1 (en) 2007-01-18
WO2007011626A2 (fr) 2007-01-25
CR9664A (es) 2009-07-07
EA200800321A1 (ru) 2008-06-30
AU2006270322A1 (en) 2007-01-25
US7732475B2 (en) 2010-06-08
US20080108829A1 (en) 2008-05-08
IL188692A0 (en) 2008-08-07
US20090105485A1 (en) 2009-04-23
KR20080032188A (ko) 2008-04-14
PE20070195A1 (es) 2007-05-06
AR054866A1 (es) 2007-07-25

Similar Documents

Publication Publication Date Title
MA31763B1 (fr) Inhibiteurs de kinase de type polo
TW200740761A (en) Histone deacetylase inhibitors
MA33261B1 (fr) Sulfonamides nématocides
MX2008000141A (es) Moduladores de lxr basados en imidazol.
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA31147B1 (fr) 4-phenyl-pyrane-3.5-diones ,4-phenyl-thiopyrane-3.5- diones et cyclohexanetriones en tant que nouveaux herbicides
EA200900959A1 (ru) Ингибиторы мек
MY162157A (en) Substituted indole mcl-1 inhibitors
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA33562B1 (fr) Mélanges de pesticides méso-ioniques
CY1109331T1 (el) Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
MA33560B1 (fr) Pesticides mésoioniques
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
WO2007084390A3 (fr) Inhibiteurs des histone desacetylases
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
EP3976604A4 (fr) Composés dérivés de 1,3,4-oxadiazole utilisés comme inhibiteurs d'histone désacétylase 6, et composition pharmaceutique les comprenant
MA31597B1 (fr) Nouveaux herbicides
MA31623B1 (fr) Nouveaux herbicides
GT200800227A (es) Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos
MA33328B1 (fr) Composés insecticides
DK1899325T3 (da) Imidazolinon- og hydantoinderivater som hidtil ukendte hæmmere af histondeacetylase
MY148098A (en) Quinolone compound and pharmaceutical composition